Avidity Biosciences Receives Clearance From FDA for AOC1020 and AOC 1044 Clinical Trials

On September 27, 2022, Avidity shared that they received IND clearance from the FDA to proceed with the clinical trial of AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping.

Read their full press release here.


Avidity Duchenne News Update:

September 27, 2022: We are pleased to announce that we have received IND clearance from the FDA to proceed with the clinical trial of AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and AOC 1044 for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 44 skipping. These programs are advancing into the clinic. We look forward to sharing additional information about these programs in the coming weeks.